HRS-4642 in Combination With AG for Neoadjuvant and Adjuvant Treatment of Pancreatic Cancer

This study is testing a new drug called HRS-4642 combined with standard chemotherapy (gemcitabine and albumin-bound paclitaxel, abbreviated AG) as a treatment before and after surgery for patients with resectable or borderline resectable pancreatic cancer — meaning cancer that may be removable with surgery. **You may be eligible if...** - You are between 18 and 80 years old - You have confirmed pancreatic ductal adenocarcinoma (the most common type of pancreatic cancer) - Your cancer is classified as resectable or borderline resectable by imaging (following NCCN guidelines) - You have at least one measurable tumor on imaging - Your overall health and organ function meet the study requirements **You may NOT be eligible if...** - Your cancer has spread to distant organs (metastatic) - You have previously received treatment for this cancer - You have serious heart, liver, or kidney conditions - You are pregnant or breastfeeding - You have active uncontrolled infections Talk to your doctor to see if this trial is right for you.